Neutropenia: Follow-up

References

1. Watts RG. Neutropenia. In: Lee GR, Foerster J, Lukens J, et al, eds. Wintrobe's Clinical Hematology. 10^th ed. Baltimore, Md: Lippincott, Williams & Wilkins; 1999:1862-1888.

2. Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer. Sep 2009;101 Suppl 1:S6-10. [Medline].

3. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer. Sep 2009;101 Suppl 1:S11-4. [Medline].

4. Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer. Sep 2009;101 Suppl 1:S23-6. [Medline].

5. Sifton DW, Murray L, Kelly GL, Reilly S, eds. Physicians' Desk Reference. 55^th ed. Montvale, NJ: Medical Economics Company, Inc.; 2001:551-6, 847-60, 1275-80, 1396-9, 1793-5, 1998-2002, 3068-71.

6. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. Nov 1994;12(11):2471-508. [Medline]. [Full Text].

7. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. Jun 1996;14(6):1957-60. [Medline].

8. Vial T, Gallant C, Choqu-Kastylevsky G, Descotes J. Treatment of drug-induced agranulocytosis with haematopoietic growth factors: a review of the clinical experience. BioDrugs. Mar 1999;11(3):185-200. [Medline].

9. D'Angelo G. Ethnic and genetic causes of neutropenia: clinical and therapeutic implications. Lab Hematol. 2009;15(3):25-9. [Medline].

10. [Best Evidence] Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. Oct 8 2008;CD003189. [Medline]. [Full Text].

11. D'Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. Oct 2008;22(4):280-90. [Medline].

12. Carlsson G, Aprikyan AA, Ericson KG, et al. Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern Sweden. Haematologica. May 2006;91(5):589-95. [Medline]. [Full Text].

13. Xia J, Bolyard AA, Rodger E, Stein S, Aprikyan AA, Dale DC, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. Sep 22 2009;[Medline].

14. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. Sep 1997;25(3):551-73. [Medline].

15. Dranitsaris G, Rayson D, Vincent M, et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol. Aug 2008;31(4):369-74. [Medline].

16. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. Mar 11 1999;340(10):764-71. [Medline]. [Full Text].

17. Alanis A, Rehm S, Weinstein AJ. Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients. Cleve Clin Q. Winter 1983;50(4):385-95. [Medline].

18. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. Feb 1966;64(2):328-40. [Medline].

19. Boocock GR, Marit MR, Rommens JM. Phylogeny, sequence conservation, and functional complementation of the SBDS protein family. Genomics. Jun 2006;87(6):758-71. [Medline].

20. Bow EJ, Mandell LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med. Aug 1 1996;125(3):183-90. [Medline]. [Full Text].

21. Finberg RW, Talcott JA. Fever and neutropenia--how to use a new treatment strategy. N Engl J Med. Jul 29 1999;341(5):362-3. [Medline].

22. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. Jul 29 1999;341(5):305-11. [Medline]. [Full Text].

23. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. Jul 29 1999;341(5):312-8. [Medline]. [Full Text].

24. Liu JM, Ellis SR. Ribosomes and marrow failure: coincidental association or molecular paradigm?. Blood. Jun 15 2006;107(12):4583-8. [Medline]. [Full Text].

25. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med. Oct 1 1994;121(7):492-501. [Medline]. [Full Text].

26. Mangan JK, Russell JE. Profound neutropenia resulting from metyrapone-induced adrenal crisis. Am J Hematol. Aug 10 2009;[Medline].

27. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med. Jun 1 1994;120(11):913-8. [Medline]. [Full Text].

28. Park Y, Kim DS, Park SJ, Seo HY, Lee SR, Sung HJ, et al. The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leuk Res. Sep 15 2009;[Medline].

29. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. Aug 28 1986;315(9):552-8. [Medline].

30. Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis. Jan 1978;137(1):14-29. [Medline].

31. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. Dec 1988;148(12):2561-8. [Medline].

32. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. Feb 1992;10(2):316-22. [Medline].

33. Young NS. Agranulocytosis. JAMA. Mar 23-30 1994;271(12):935-8. [Medline].

Further Reading

Related eMedicine Topics

• Agranulocytosis
• Autoimmune and Chronic Benign Neutropenia [in the Pediatrics: General Medicine section]
• Granulocytopenia
• Kostmann Disease [in the Pediatrics: General Medicine section]

• Fatigue and Symptom Burden in Febrile Neutropenia
• Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

• ACR Appropriateness Criteria® fever without source - child. American College of Radiology - Medical Specialty Society. 1999 (revised 2008). 8 pages. NGC:007009
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. American Society of Clinical Oncology - Medical Specialty Society. 1994 Nov (revised 2006 Jul 1). 19 pages. NGC:005040

Keywords

neutropenia, Schultz disease, agranulocytosis, granulocytopenia, leukopenia, neutropenic fever, circulating neutrophils, granulocyte colony-stimulating factor, G-CSF, bone marrow transplantation, Kostmann syndrome, Shwachman-Diamond syndrome, Zinsser-Cole-Engman syndrome

Contributor Information and Disclosures

Author

John E Godwin, MD, MS, Professor of Medicine, Chief Division of Hematology/Oncology, Associate Director, Simmons Cooper Cancer Institute, Southern Illinois University School of Medicine
John E Godwin, MD, MS is a member of the following medical societies: American Association for the Advancement of Science, American Heart Association, and American Society of Hematology
Disclosure: Nothing to disclose.

Coauthor(s)

Christopher D Braden, DO, Attending Physician, Department of Hematology and Oncology, St. Francis Cancer Center, Indianapolis, Indiana.
Disclosure: Nothing to disclose.

Medical Editor

Karen Seiter, MD, Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College
Karen Seiter, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, and American Society of Hematology
Disclosure: Novartis Honoraria Speaking and teaching; Schering Honoraria Speaking and teaching; Cephalon Honoraria Speaking and teaching

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Troy H Guthrie, Jr, MD, Director of Cancer Institute, Baptist Medical Center
Troy H Guthrie, Jr, MD is a member of the following medical societies: American Federation for Medical Research, American Medical Association, American Society of Hematology, Florida Medical Association, Medical Association of Georgia, and Southern Medical Association
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.